Impact of isoniazid monoresistance on overall and vulnerable patient populations in Taiwan.
Humans
Isoniazid
/ pharmacology
Taiwan
/ epidemiology
Antitubercular Agents
/ pharmacology
Male
Female
Middle Aged
Adult
Tuberculosis, Pulmonary
/ drug therapy
Aged
Mycobacterium tuberculosis
/ drug effects
Drug Resistance, Bacterial
Vulnerable Populations
Treatment Outcome
Sputum
/ microbiology
Retrospective Studies
Young Adult
Tuberculosis, Multidrug-Resistant
/ drug therapy
Rifampin
/ pharmacology
Drug-susceptible
isoniazid resistance
mortality
sputum culture conversion
tuberculosis
Journal
Emerging microbes & infections
ISSN: 2222-1751
Titre abrégé: Emerg Microbes Infect
Pays: United States
ID NLM: 101594885
Informations de publication
Date de publication:
Dec 2024
Dec 2024
Historique:
medline:
24
10
2024
pubmed:
15
10
2024
entrez:
15
10
2024
Statut:
ppublish
Résumé
Isoniazid is an early bactericidal anti-tuberculosis (TB) agent and isoniazid mono-resistance TB is the most prevalent drug-resistant TB worldwide. Concerns exist regarding whether resistance to isoniazid would lead to delayed culture conversion and worst outcomes. From January 2008 to November 2017, adult culture-positive pulmonary TB patients receiving isoniazid, rifampicin, pyrazinamide, and ethambutol were identified through Taiwan Center for Disease Control database and were followed until the end of 2017. Primary outcomes included time to sputum culture conversion (SCC) within two months. Secondary outcomes included death and unfavourable outcomes at the end of 2nd month. A total of 37,193 drug-susceptible and 2,832 isoniazid monoresistant pulmonary TB patients were identified. Compared with no resistance, isoniazid monoresistance was not associated with a delayed SCC (HR: 0.99, 95% CI: 0.94─1.05,
Identifiants
pubmed: 39404086
doi: 10.1080/22221751.2024.2417855
doi:
Substances chimiques
Isoniazid
V83O1VOZ8L
Antitubercular Agents
0
Rifampin
VJT6J7R4TR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM